Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Completed · Phase 1

Conditions studied: Psoriasis Vulgaris

In brief

The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)

Key facts

Study ID
NCT00306878
Run by
Bristol-Myers Squibb
People needed
45
Starts
1995-08-01
Expected to finish
1997-05-01
Last updated by the study team
2011-04-13

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.